ITM Isotope Technologies Munich SE has received a Complete Response Letter from the U.S. Food and Drug Administration, blocking approval of its cancer drug ITM-11.
The FDA issued the CRL on August 7, 2026, in response to ITM’s New Drug Application for 177Lu-edotreotide, also known as ITM-11, targeting gastroenteropancreatic neuroendocrine tumors.
Regulators made clear that the rejection was not related to the drug’s clinical performance, but instead cited chemistry, manufacturing, and controls issues alongside concerns about a third-party commercial facility.
The problems must be fully resolved before the FDA will consider approving the application in any revised form, adding uncertainty to the drug’s commercial timeline.
ITM-11 is a radiopharmaceutical, a class of treatment designed to deliver radioactive isotopes directly to tumor cells, sparing surrounding healthy tissue from unnecessary radiation exposure.
The drug targets gastroenteropancreatic neuroendocrine tumors, a rare cancer that develops in the pancreas, stomach, small intestine, and other parts of the gastrointestinal system.
ITM-11 uses the isotope lutetium-177 paired with a compound targeting the somatostatin receptor, placing it in the same therapeutic territory as Novartis’s already-approved radiopharmaceutical Lutathera.
Clinical data from the pivotal COMPETE trial showed that patients with early-stage GEP-NETs receiving ITM-11 went a median 23.9 months without tumor progression, compared to 14.1 months for patients on everolimus.
The FDA had originally set a Prescription Drug User Fee Act goal date of August 28, 2026, meaning the CRL arrived ahead of that regulatory deadline.
ITM CEO Dr. Andrew Cavey responded to the setback with a firm commitment to resolving the outstanding issues raised by the agency.
Dr. Cavey said: “Our confidence in ITM-11’s therapeutic potential has not wavered, and we are committed to working closely with the FDA and our partners to address the items outlined in the CRL.”
He added: “Our pivotal COMPETE trial data package stands, and our goal remains unchanged as we work toward bringing ITM-11 to patients living with advanced GEP-NETs.”
The manufacturing stumble is a significant but not uncommon obstacle in the radiopharmaceutical space, where complex production requirements frequently draw regulatory scrutiny before approval.
ITM now faces the task of satisfying the FDA’s facility and manufacturing requirements while maintaining momentum in a competitive and fast-growing radiopharmaceutical market.